How Cardiologists’ High Hopes for Two Drugs Were Dashed
By every measure, the drugs were no better than placebos, full data revealed on Saturday. Was it the fault of the design of the studies, or our very hypotheses about heart disease?
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- Timing: It landed over the weekend, so Monday's session is the first that could react.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. No single company here, so if this one leaves a mark it tends to show first in the indexes, Treasury yields and the dollar — all live on the Markets page.
What to watch next
No company to chase here, so pull the backdrop thread instead — the Markets page shows how the indexes are taking it. If it touches a company you follow, that company's page carries the prices and coverage this one cannot. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. Wook AI, up top, can look up any company the story touches and pull its live figures — no tab-hopping required.
Discussion
No one has weighed in yet. Start the discussion on this story.